Literature DB >> 9390026

Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas.

D Schullerus1, J Herbers, J Chudek, H Kanamaru, G Kovacs.   

Abstract

In this study, 105 non-papillary renal cell carcinomas (RCCs) have been examined for allelic loss at the chromosome 8p12-21.1, 9p21, and 14q24.2-qter regions, each by two highly polymorphic microsatellites. Loss of heterozygosity (LOH) was detected at both chromosome 8p and 9p in 33 per cent of the cases and at chromosome 14q in 45 per cent of the tumours. A correlation of variables such as size, grade, and stage of tumours with these specific genetic alterations showed that loss of chromosomes 8p and 9p, and especially loss of chromosome 14q regions, is significantly associated with a higher grade of tumour and the combined LOH at these chromosomal sites with advanced tumour stage. These genetic alterations did not show any correlation with the size of non-papillary RCCs. This study suggests that genetic markers at the above-mentioned chromosomal sites can predict the clinical outcome of non-papillary RCCs.

Entities:  

Mesh:

Year:  1997        PMID: 9390026     DOI: 10.1002/(SICI)1096-9896(199710)183:2<151::AID-PATH928>3.0.CO;2-R

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

2.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma.

Authors:  Reza Nejati; Shuanzeng Wei; Robert G Uzzo; Sahar Poureghbali; Jianming Pei; Jacqueline N Talarchek; Karen Ruth; Essel Dulaimi; Alexander Kutikov; Joseph R Testa; Tahseen Al-Saleem
Journal:  Clin Genitourin Cancer       Date:  2019-09-26       Impact factor: 2.872

Review 4.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 5.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

6.  Acquired cystic disease-associated renal cell carcinoma: an immunohistochemical and fluorescence in situ hybridization study.

Authors:  Naoto Kuroda; Motoki Yamashita; Yoshiyuki Kakehi; Ondrej Hes; Michal Michal; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-12-17       Impact factor: 2.309

Review 7.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

8.  Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma.

Authors:  Melinda E Sanders; Rosemarie Mick; John E Tomaszewski; Frederic G Barr
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

9.  Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes.

Authors:  F Jiang; J Richter; P Schraml; L Bubendorf; T Gasser; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Authors:  Meng Chen; Yuanqing Ye; Hushan Yang; Pheroze Tamboli; Surena Matin; Nizar M Tannir; Christopher G Wood; Jian Gu; Xifeng Wu
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.